아시아 태평양 비강 스프레이 시장 – 2030년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

아시아 태평양 비강 스프레이 시장 – 2030년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Apr 2023
  • Asia-Pacific
  • 350 Pages
  • 테이블 수: 110
  • 그림 수: 47

Asia Pacific Nasal Spray Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2023 –2030
Diagram 시장 규모(기준 연도)
백만 달러
Diagram 시장 규모(예측 연도)
미국 달러 6,248.16
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>아시아 태평양 비강 스프레이 시장, 제품 유형별(비강 충혈 완화 스프레이, 스테로이드 비강 스프레이, 식염수 용액/식염수 비강 스프레이 및 기타), 용기 디자인(펌프 병 및 가압 용기), 투여 형태(다중 투여, 단위/단일 투여 및 2회 투여), 치료적 분류(항히스타민제, 비강 스테로이드, 비만 세포 억제제 및 항콜린제), 응용 분야(비강 충혈, 알레르기 및 비알레르기 비염, 중추 신경계 장애, 예방 접종 및 기타), 처방/이용 가능성(처방전 없이 구입 가능한 약 및 처방약), 최종 사용자(가정 요양 시설, 병원, 진료소 및 지역 사회 건강 관리) - 산업 동향 및 2030년까지의 예측.

아시아 태평양 비강 스프레이 시장

아시아 태평양 비강 스프레이 시장 분석 및 통찰력

알레르기성 비염 은 전 세계 5억 명 이상의 사람들에게 문제를 일으키는 주요 건강 문제입니다. 비강 막힘, 코골이, 후비루, 기침, 후각 감소, 두통 등의 증상이 지구상 환자의 거의 절반에게 수개월 또는 수년간 나타납니다. 이러한 증상은 환자의 삶의 질에도 영향을 미칠 수 있습니다.

아시아 태평양 비강 스프레이 시장아시아 태평양 비강 스프레이 시장

비강 스프레이는 비강 막힘, 감염, 가려움증이나 눈물, 콧물, 가슴 막힘, 기침, 천명, 호흡 곤란, 얕은 호흡 등과 같은 주요 알레르기 문제를 치료하기 위한 비강 약물 전달 시스템으로 널리 사용되는 장치입니다. 비강 용종, 염증성 장 질환, 신장 관련 문제 등을 포함하는 다른 질병도 있습니다. 스프레이의 도움으로 복용 형태로 코로 약물이나 약물을 투여하는 것은 환자의 신체에서 약물의 빠른 작용을 제공하는 비침습적 기술입니다. 비강 스프레이는 가장 비용 효율적인 방법 중 하나이며 침습이 필요하지 않으며 사용하기 쉽고 스스로 투여할 수 있으며 환자의 준수도가 높습니다. 따라서 비강 약물 전달은 최근 인기 있는 약물 투여 경로 중 하나이며 강력한 성장 기회가 있습니다.

비강 스프레이는 비강 알레르기, 코막힘, 만성 부비동염, 알레르기성 비염 및 코와 관련된 기타 문제와 같은 비강 질환을 치료하기 위한 일반 의약품(OTC) 또는 처방약으로 시중에 판매됩니다. 이러한 스프레이는 펌프 또는 캐니스터 형태로 시중에 판매됩니다.

Data Bridge Market Research에 따르면 아시아태평양 비강 스프레이 시장은 2030년까지 62억 4,816만 달러 규모에 도달할 것으로 예상되며, 이는 예측 기간 동안 연평균 성장률 7.1%를 기록할 것으로 예상됩니다.

보고서 메트릭

세부

예측 기간

2023년부터 2030년까지

기준 연도

2022

역사적 해

2021 (2015-2020까지 사용자 정의 가능)

양적 단위

매출은 백만, 볼륨은 단위, 가격은 USD로 표시

다루는 세그먼트

Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care)

Countries Covered

China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, and Rest of Asia-Pacific

Market Players Covered

EMERGENT, Cipla Inc., Sandoz International GmbH (A Part of Novartis), Aytu Health (A subsidiary of Aytu BioPharma, Inc.), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., J Pharmaceuticals, St. Renatus., Ultratech India Limited, Catalent, Inc., Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd), Pfizer Inc., Viatris Inc., LEEFORD HEALTHCARE LTD, and Aishwarya Group among others

Market Definition

Nasal sprays are devices that help in the delivery of the drug through the nose in the nasal cavity to treat allergies and other problems related to brain inflammation, diabetes, dental problems, and the central nervous system. Allergy is a condition in which the immune system of the body reacts abnormally to a foreign substance. Nasal spray drug products consist of therapeutically active ingredients or drug substances in the form of solution or suspension of excipients.

There are different types of nasal spray available in the market, such as decongestion nasal spray, saline nasal spray, and steroid nasal spray. Decongestants are devices with drugs for the treatment of nasal congestion and provide short-term relief from a blocked nose. The decongestion nasal spray consists of drugs that open up the airways of the nasal part and helps in the breathing process.

During the cold and dry winter season, saline nasal sprays are used to avoid problems related to a stuffy nose. These devices are used to treat sinusitis, nasal crusting, and thin secretions of liquid from the nose, which are formed due to bacterial infection and lead to the dryness of the nasal area. This device helps in cleaning the nasal passage and mucus present in that area due to cold.

Asia-Pacific Nasal Spray Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVER

  • Increase in Infection and Allergic Cases

Allergy is a condition that makes the immune system weaken, and the immune system reacts abnormally to a foreign substance. Allergies have many forms, such as Allergic Rhinitis (AR), and this affects nearly 40 to 50 million people in the U.S. Some allergies may interfere with day-to-day activities and the quality of life.

Due to the increase in population, urbanization, and industrialization has increased tremendously, which has led to a rise in allergen. This allergen is responsible for allergies or infectious diseases in many people.

Thus, the rise in the prevalence of allergic diseases such as AR has led to an increase in the demand for nasal sprays, which is expected to drive market growth in the coming years.

RESTRAINT

  • Adverse Effects of Using Nasal Sprays

Many people opt for nasal sprays in order to get relief from a runny and stuffy nose, but using a nasal spray for a longer period of time causes several side effects. Steroid nasal sprays, also called corticosteroid nasal sprays, are anti-inflammatory medicines that are sprayed into the nose. They can be used to treat a range of conditions, including hay fever, sinusitis, non-allergic rhinitis, and nasal polyps. Some steroid nasal sprays are available to buy from pharmacies and shops, while others are only available on prescription.

Using nasal sprays for a prolonged period of time can lead to bleeding from the nose and even headaches. Some may experience other side effects, such as addiction or even congestion.

If one is taking a high dose for a long time, there is also a small chance one could get some of the side effects of steroid tablets, such as increased appetite, mood changes, and difficulty sleeping.

Thus, the adverse effects of nasal sprays are expected to restrain the market growth.

OPPORTUNITY

  • Expanding Therapeutic Applications for Nasal Sprays

Intranasal administration provides various useful options for the local and systemic delivery of diverse therapeutic agents for the treatment of problems such as allergies, respiratory diseases, and many others.

A nasal spray is one of the recently developed products, such as OptiNose and ViaNase, that helps to enable the targeting of formulations to a specific area of the site in the nasal cavity in humans.

Nasal therapy has been known as a form of treatment in Indian medicine for decades. It is also called “NASAYA KARMA” in Ayurvedic systems in Indian medicine.

The nasal spray consists of one or more than one therapeutically active ingredients in the form of suspension or solution in a non-pressurized dispenser. The most common allergy is AR.

Apart from respiratory problems, there are other therapeutic areas such as orthopedic, renal, and many other areas, where the nasal spray is playing important role in treating and curing such problems. In the future, other treatments may be developed that can help in the treatment of other problems easily.

CHALLENGE

  • Regulatory Hurdles

Nasal drug delivery can be evaluated by many regulatory agencies, such as the U.S. FDA and the European Medicines Agency (EMA). These agencies provide a set of guidelines and regulations for any product before it is launched in the market. They allow performing various in vitro test methods for determining the characterization of nasal drug products and that should come in an acceptable range as given by such regulatory bodies.

Nasal spray can be designed as per the dose requirement of drug substances for patients suffering from nasal or any other issues. Some aspects of nasal sprays may be exceptional in the case of formulation, manufacturing, container closure system, stability, controls of critical steps, intermediates, and drug products. These aspects should be measured carefully while developing a program of nasal spray. Because of these changes ability of the product to treat patients may get affected.

Strict rules and regulations for the product for nasal spray manufacturing are more challenging for the manufacturer to get approval from regulatory agencies. The spray characteristics can be influenced by the design of the device, and by the handling of the device. Performing such tests to get the perfect result, that is, an acceptable range as given by the regulatory body, is more challenging in nasal spray manufacturing.

Post-COVID-19 Impact Analysis on the Asia-Pacific Nasal Spray Market

COVID-19 had a significant impact on the generic drug market for inhalation and nasal spray, as one of the main symptoms associated with COVID-19 is shortness of breath. The demand for inhalation and nasal spray increased during the pandemic.

For instance,

  • According to a MedComm journal article published in 2021, nasal sprays demonstrated the ability to be an effective COVID-19 treatment and vaccine option

Spray formulations that may inactivate SARS-CoV-2 or restrict its entry into cells were thought to be beneficial in preventing viral spread to the lungs or surrounding people. Relaxed lockdowns and the resumption of healthcare practices are expected to accelerate market growth in the post-pandemic era. COVID-19 patients are still experiencing long-term side effects such as shortness of breath.

Recent Developments

  • In January 2023, Viatris Inc. (NASDAQ: VTRS), a Asia-Pacific healthcare company, today announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. This acquisition would help the company in its business expansion.
  • In March 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd, announced the launch of additional strengths for the generic version of Revlimid1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the U.S. This product launch would help the company in its product portfolio expansion.

Asia-Pacific Nasal Spray Market Scope

The Asia-Pacific nasal spray market is segmented into seven notable segments on the basis of product type, container design, dosage form, therapeutic class, application, prescription/ availability, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

PRODUCT TYPE

  • DECONGESTION NASAL SPRAY
  • STEROID NASAL SPRAY
  • SALT WATER SOLUTION/ SALINE NASAL SPRAY
  • OTHERS

On the basis of product type, the market is segmented into decongestion nasal spray, salt water solution/saline nasal spray, steroid nasal spray, and others.

CONTAINER DESIGN

  • PUMP BOTTLES
  • PRESSURIZED CANISTERS

On the basis of container design, the market is segmented into pressurized canisters and pump bottles.

DOSAGE FORM

  • MULTI DOSE
  • UNIT/SINGLE DOSE
  • BI DOSE

On the basis of dosage form, the market is segmented into unit/single dose, bi dose, and multi dose.

THERAPEUTIC CLASS

  • ANTIHISTAMINE
  • NASAL STEROIDS
  • MAST CELL INHIBITOR
  • ANTICHOLINERGIC

On the basis of therapeutic class, the market is segmented into antihistamine, nasal steroids, mast cell inhibitor, and anticholinergic.

APPLICATION

  • NASAL CONGESTION
  • ALLERGIC AND NON-ALLERGIC RHINITIS
  • CENTRAL NERVOUS SYSTEM DISORDERS
  • VACCINATION
  • OTHERS

On the basis of application, the market is segmented into nasal congestion, allergic and non-allergic rhinitis, central nervous system disorders, vaccination, and others.

PRESCRIPTION/AVAILABILITY

  • OVER THE COUNTER
  • PRESCRIBED

On the basis of prescription/availability, the market is segmented into over the counter and prescribed.

END USER

  • HOME CARE SETTINGS
  • HOSPITALS
  • CLINICS
  • COMMUNITY HEALTH CARE

On the basis of end user, the market is segmented into home care settings, hospitals, clinics, and community health care.

비강 스프레이 시장

Asia-Pacific Nasal Spray Market Regional Analysis/Insights

The Asia-Pacific nasal spray market is segmented into seven notable segments on the basis of product type, container design, dosage form, therapeutic class, application, prescription/ availability, and end user.

The countries covered in this market report are China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, and the rest of Asia-Pacific.

In 2023, China is dominating the Asia-Pacific nasal spray market due to increasing customer inclinations toward nasal spray.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 국내 시장의 개별 시장 영향 요인과 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 아시아 태평양 비강 스프레이 시장 점유율 분석

아시아 태평양 비강 스프레이 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭과 범위, 적용 우세, 제품 유형 수명선 곡선입니다. 제공된 위의 데이터 포인트는 회사가 시장에 집중하는 것과만 관련이 있습니다.

아시아 태평양 비강 스프레이 시장에서 활동하는 주요 기업으로는 EMERGENT, Cipla Inc., Sandoz International GmbH(Novartis의 일부), Aytu Health(Aytu BioPharma, Inc.의 자회사), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., J Pharmaceuticals, St. Renatus., Ultratech India Limited, Catalent, Inc., Teva Pharmaceuticals USA, Inc.(Teva Pharmaceutical Industries Ltd의 자회사), Pfizer Inc., Viatris Inc., LEEFORD HEALTHCARE LTD, Aishwarya Group 등이 있습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES MODEL

4.2 PESTEL ANALYSIS

5 INDUSTRY INSIGHTS: ASIA PACIFIC NASAL SPRAY MARKET

5.1 INDUSTRY INSIGHTS

6 REGULATIONS: ASIA PACIFIC NASAL SPRAY MARKET

6.1 REGULATORY SCENARIO IN INDIA

6.2 REGULATORY SCENARIO IN CHINA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES

7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA

7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY

7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY

7.2 RESTRAINTS

7.2.1 PRODUCT RECALLS

7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS

7.3 OPPORTUNITIES

7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY

7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS

7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS

7.4 CHALLENGES

7.4.1 REGULATORY HURDLES

7.4.2 ADDICTION TO NASAL SPRAY

8 ASIA PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 DECONGESTION NASAL SPRAY

8.3 STEROID NASAL SPRAY

8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY

8.5 OTHERS

9 ASIA PACIFIC NASAL SPRAY MARKET, BY CONTAINER DESIGN

9.1 OVERVIEW

9.2 PUMP BOTTLES

9.3 PRESSURIZED CANISTERS

10 ASIA PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM

10.1 OVERVIEW

10.2 MULTI DOSE

10.3 UNIT/SINGLE DOSE

10.4 BI DOSE

11 ASIA PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS

11.1 OVERVIEW

11.2 ANTIHISTAMINE

11.3 NASAL STEROIDS

11.4 MAST CELL INHIBITOR

11.5 ANTICHOLINERGIC

12 ASIA PACIFIC NASAL SPRAY MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 NASAL CONGESTION

12.3 ALLERGIC AND NON-ALLERGIC RHINITIS

12.4 CENTRAL NERVOUS SYSTEM DISORDERS

12.5 VACCINATION

12.6 OTHERS

13 ASIA PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY

13.1 OVERVIEW

13.2 PRESCRIBED

13.3 OVER THE COUNTER

14 ASIA PACIFIC NASAL SPRAY MARKET, BY END USER

14.1 OVERVIEW

14.2 HOME CARE SETTINGS

14.3 HOSPITALS

14.4 CLINICS

14.5 COMMUNITY HEALTH CARE

15 ASIA PACIFIC NASAL SPRAY MARKET, BY REGION

15.1 ASIA-PACIFIC

15.1.1 CHINA

15.1.2 JAPAN

15.1.3 INDIA

15.1.4 AUSTRALIA

15.1.5 SOUTH KOREA

15.1.6 MALAYSIA

15.1.7 THAILAND

15.1.8 SINGAPORE

15.1.9 INDONESIA

15.1.10 PHILIPPINES

15.1.11 REST OF ASIA-PACIFIC

16 ASIA PACIFIC NASAL SPRAY MARKET, COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 GLAXOSMITHKLINE PLC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 PFIZER INC.

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 EMERGENT

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS)

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 CATALENT, INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENTS

18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.)

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENTS

18.7 AISHWARYA GROUP

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENTS

18.8 ASSERTIO THERAPEUTICS, INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENT

18.9 AURENA LABORATORIES.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENTS

18.1 BAYER AG

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 COMPANY SHARE ANALYSIS

18.10.4 PRODUCT PORTFOLIO

18.10.5 RECENT DEVELOPMENTS

18.11 CIPLA INC.

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.12 J PHARMACEUTICALS.

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENTS

18.13 LEEFORD HEALTHCARE LTD

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENTS

18.14 ST. RENATUS.

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENTS

18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD)

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENTS

18.16 ULTRATECH INDIA LIMITED

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENTS

18.17 VIATRIS INC.

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 COMPANY SHARE ANALYSIS

18.17.4 PRODUCT PORTFOLIO

18.17.5 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

표 목록

TABLE 1 ASIA PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 2 ASIA PACIFIC DECONGESTION NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 ASIA PACIFIC STEROID NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 ASIA PACIFIC SALT WATER SOLUTION/SALINE NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 ASIA PACIFIC OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 ASIA PACIFIC NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 7 ASIA PACIFIC PUMP BOTTLES IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 ASIA PACIFIC PRESSURIZED CANISTERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 ASIA PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 10 ASIA PACIFIC MULTI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 ASIA PACIFIC UNIT/SINGLE DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 ASIA PACIFIC BI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 ASIA PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 14 ASIA PACIFIC ANTIHISTAMINE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 ASIA PACIFIC NASAL STEROIDS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 ASIA PACIFIC MAST CELL INHIBITOR IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 ASIA PACIFIC ANTICHOLINERGIC IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 ASIA PACIFIC NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 19 ASIA PACIFIC NASAL CONGESTION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 ASIA PACIFIC ALLERGIC AND NON-ALLERGIC RHINITIS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 ASIA PACIFIC CENTRAL NERVOUS SYSTEM DISORDERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 ASIA PACIFIC VACCINATION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 ASIA PACIFIC OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 ASIA PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 25 ASIA PACIFIC PRESCRIBED IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 ASIA PACIFIC OVER THE COUNTER IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 ASIA PACIFIC NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 28 ASIA PACIFIC HOME CARE SETTINGS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 ASIA PACIFIC HOSPITALS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 ASIA PACIFIC CLINICS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 ASIA PACIFIC COMMUNITY HEALTH CARE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 ASIA-PACIFIC NASAL SPRAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 33 ASIA-PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 34 ASIA-PACIFIC NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 35 ASIA-PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 36 ASIA-PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 37 ASIA-PACIFIC NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 38 ASIA-PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 39 ASIA-PACIFIC NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 40 CHINA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 41 CHINA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 42 CHINA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 43 CHINA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 44 CHINA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 45 CHINA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 46 CHINA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 47 JAPAN NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 48 JAPAN NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 49 JAPAN NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 50 JAPAN NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 51 JAPAN NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 52 JAPAN NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 53 JAPAN NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 54 INDIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 INDIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 56 INDIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 57 INDIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 58 INDIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 59 INDIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 60 INDIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 61 AUSTRALIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 62 AUSTRALIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 63 AUSTRALIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 64 AUSTRALIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 65 AUSTRALIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 66 AUSTRALIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 67 AUSTRALIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 68 SOUTH KOREA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 69 SOUTH KOREA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 70 SOUTH KOREA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 71 SOUTH KOREA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 72 SOUTH KOREA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 73 SOUTH KOREA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 74 SOUTH KOREA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 75 MALAYSIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 76 MALAYSIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 77 MALAYSIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 78 MALAYSIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 79 MALAYSIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 80 MALAYSIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 81 MALAYSIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 82 THAILAND NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 83 THAILAND NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 84 THAILAND NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 85 THAILAND NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 86 THAILAND NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 87 THAILAND NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 88 THAILAND NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 89 SINGAPORE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 90 SINGAPORE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 91 SINGAPORE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 92 SINGAPORE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 93 SINGAPORE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 94 SINGAPORE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 95 SINGAPORE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 96 INDONESIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 97 INDONESIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 98 INDONESIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 99 INDONESIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 100 INDONESIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 101 INDONESIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 102 INDONESIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 103 PHILIPPINES NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 104 PHILIPPINES NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 105 PHILIPPINES NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 106 PHILIPPINES NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 107 PHILIPPINES NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 108 PHILIPPINES NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 109 PHILIPPINES NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 110 REST OF ASIA-PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

그림 목록

FIGURE 1 ASIA PACIFIC NASAL SPRAY MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC NASAL SPRAY MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC NASAL SPRAY MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC NASAL SPRAY MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC NASAL SPRAY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC NASAL SPRAY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC NASAL SPRAY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC NASAL SPRAY MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 ASIA PACIFIC NASAL SPRAY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC NASAL SPRAY MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN INFECTION AND ALLERGIC CASES IS EXPECTED TO DRIVE THE ASIA PACIFIC NASAL SPRAY MARKET IN THE FORECAST PERIOD

FIGURE 12 THE DECONGESTION NASAL SPRAY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC NASAL SPRAY MARKET IN 2023 AND 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC NASAL SPRAY MARKET

FIGURE 14 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, 2022

FIGURE 15 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 16 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 17 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 18 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2022

FIGURE 19 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2023-2030 (USD MILLION)

FIGURE 20 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, CAGR (2023-2030)

FIGURE 21 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, LIFELINE CURVE

FIGURE 22 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, 2022

FIGURE 23 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, 2023-2030 (USD MILLION)

FIGURE 24 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, CAGR (2023-2030)

FIGURE 25 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 26 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2022

FIGURE 27 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2023-2030 (USD MILLION)

FIGURE 28 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, CAGR (2023-2030)

FIGURE 29 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, LIFELINE CURVE

FIGURE 30 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, 2022

FIGURE 31 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 32 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 33 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 34 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2022

FIGURE 35 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2023-2030 (USD MILLION)

FIGURE 36 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, CAGR (2023-2030)

FIGURE 37 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, LIFELINE CURVE

FIGURE 38 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, 2022

FIGURE 39 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 40 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, CAGR (2023-2030)

FIGURE 41 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, LIFELINE CURVE

FIGURE 42 ASIA-PACIFIC NASAL SPRAY MARKET: SNAPSHOT (2022)

FIGURE 43 ASIA-PACIFIC NASAL SPRAY MARKET: BY COUNTRY (2022)

FIGURE 44 ASIA-PACIFIC NASAL SPRAY MARKET: BY COUNTRY (2023 & 2030)

FIGURE 45 ASIA-PACIFIC NASAL SPRAY MARKET: BY COUNTRY (2022 & 2030)

FIGURE 46 ASIA-PACIFIC NASAL SPRAY MARKET: PRODUCT TYPE (2023-2030)

FIGURE 47 ASIA PACIFIC NASAL SPRAY MARKET: COMPANY SHARE 2022 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Asia-Pacific Nasal Spray Market is projected to grow at a CAGR of 7.1% during the forecast period by 2030.
The future market value of the Asia-Pacific Nasal Spray Market is expected to reach USD 6,248.16 million by 2030.
The major players in the Asia-Pacific Nasal Spray Market are EMERGENT, Cipla Inc., Sandoz International GmbH (A Part of Novartis), Aytu Health (A subsidiary of Aytu BioPharma, Inc.), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., etc.
The countries covered in the Asia-Pacific Nasal Spray Market are China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, and Rest of Asia-Pacific.